KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Free Cash Flow: 2011-2025

Historic Free Cash Flow for Travere Therapeutics (TVTX) over the last 14 years, with Sep 2025 value amounting to $14.2 million.

  • Travere Therapeutics' Free Cash Flow rose 133.35% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.8 million, marking a year-over-year increase of 77.93%. This contributed to the annual value of -$237.5 million for FY2024, which is 27.16% up from last year.
  • As of Q3 2025, Travere Therapeutics' Free Cash Flow stood at $14.2 million, which was up 184.51% from $5.0 million recorded in Q2 2025.
  • Travere Therapeutics' Free Cash Flow's 5-year high stood at $31.7 million during Q3 2021, with a 5-year trough of -$119.0 million in Q1 2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$42.5 million (2024), whereas its average is -$53.3 million.
  • As far as peak fluctuations go, Travere Therapeutics' Free Cash Flow skyrocketed by 632.93% in 2021, and later plummeted by 675.99% in 2022.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Free Cash Flow stood at -$88.5 million in 2021, then grew by 13.27% to -$76.7 million in 2022, then grew by 16.08% to -$64.4 million in 2023, then skyrocketed by 44.53% to -$35.7 million in 2024, then spiked by 133.35% to $14.2 million in 2025.
  • Its Free Cash Flow was $14.2 million in Q3 2025, compared to $5.0 million in Q2 2025 and -$42.2 million in Q1 2025.